The biopharma company's stock fell as much as 3.60 per cent during the day to ₹331 per share, the lowest level since June 6 ...

At 11:30 am on Tuesday, SJVN and Biocon stocks were among the top gainers on the Nifty Midcap 150. SJVN's shares rose 5.17 ...

Biocon Ltd (BOM:532523) reports a robust 15% increase in operating revenue, driven by biosimilars and CRDMO growth, despite ...

Biocon shares fell nearly 4% on Friday after the company posted its first-quarter (Q1) results for FY26, showing revenue growth but a sharp drop in profit. The company’s revenue from operations rose ...

Motilal Oswal is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 410 in its research ...

Revenue from operations, however, grew 1 4.8% YoY to ₹3,942 crore, against ₹3,433 crore in the year-ago period. This figure ...

Biocon Biologics Ltd, the biosimilars unit of biopharmaceutical giant Biocon and its largest revenue driver, expects to ...

Biocon's Q1 net profit declines sharply due to high base from one-time gain last year; biosimilars, CRDMO and generics drive ...

Biocon anticipates potential challenges from proposed US tariffs on pharmaceutical imports, which could squeeze profit ...

Biocon's consolidated net profit plummeted by 95% to Rs 31 crore in the June quarter, with total revenue declining to Rs ...

Biocon Ltd. reported a 95% fall in net profit for the first quarter of financial year 2026. The pharma company reported a ...

Biocon and Viatris expect to close the transaction in the second half of this year. When it happens, Viatris will have one nominee on the Biocon board of directors.